Lanzox and Lanzox-Kid contain lansoprazole 15 mg, a proton pump inhibitor indicated for the treatment of acid-related gastrointestinal disorders. Lansoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. This medication is commonly prescribed for conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger-Ellison syndrome, and erosive esophagitis. Lanzox-Kid, formulated specifically for pediatric use, provides an appropriate dosage form to manage acid-related symptoms in children. The drug is effective in promoting ulcer healing, reducing gastric acidity, and alleviating symptoms such as heartburn, regurgitation, and epigastric pain. Lansoprazole is generally well-tolerated; however, potential adverse effects may include headache, diarrhea, abdominal pain, and nausea. It is important to administer Lanzox or Lanzox-Kid before meals to optimize acid suppression. Caution is advised in patients with hepatic impairment, and long-term use should be monitored due to potential risks such as vitamin B12 deficiency and increased susceptibility to gastrointestinal infections. Lansoprazole should be used under medical supervision, with dosage adjustments based on clinical response and patient-specific factors.